Washington University School of Medicine: Drug to Slow Alzheimer's Well Tolerated Outside of Clinical Trial Setting
May 13, 2025
May 13, 2025
ST. LOUIS, Missouri, May 13 -- The Washington University School of Medicine issued the following news release:
* * *
Drug to slow Alzheimer's well tolerated outside of clinical trial setting
Side effects of lecanemab are manageable, study finds
In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions . . .
* * *
Drug to slow Alzheimer's well tolerated outside of clinical trial setting
Side effects of lecanemab are manageable, study finds
In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions . . .